Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response.

Baricitinib has recently received approval from the US Food and Drug Administration (FDA) as a promising treatment option for adults with severe alopecia areata. Beyond this indication, it has demonstrated efficacy in other conditions such as COVID-19 and rheumatoid arthritis. The drug also presents advantages related to cost, minimal invasiveness, and the absence of postoperative management. Nevertheless, its prescription requires careful consideration of potential safety and clinical implications before widespread use. We describe two patients with severe alopecia areata (baseline Severity of Alopecia Tool (SALT) score = 100), who were treated with baricitinib as an alternative to conventional therapies, both of whom showed favorable outcomes with a progressive reduction in SALT score leading to complete regrowth during a 12-month follow-up period.